Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Triumvira Immunologics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed CD19+ Large B-Cell Lymphoma including Diffuse Large B-cell Lymphoma (DLBCL) not otherwise specified (including de novo and transformed lymphoma), Primary Mediastinal Large B-cell Lymphoma, High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangement per WHO 2016 classification.
Relapsed or refractory disease after greater than 2 lines of therapy including anthracycline and anti-CD20 therapy and either having failed autologous stem cell transplant (ASCT) or being ineligible for ASCT.
ECOG 0-1.
Adequate organ function.
You may not be if
Prior treatment with any of the following: allogeneic bone marrow transplantation, gene therapy, adoptive cell transfer of any kind, including CAR T cells.
Active central nervous system (CNS) lymphoma involvement.
History or presence of clinically relevant CNS pathology.
Active inflammatory neurological disorders, autoimmune disease, or infections.